医学
赛马鲁肽
耐受性
安慰剂
药代动力学
肥胖
药品
药物开发
药理学
不利影响
内科学
安全概况
减肥
临床试验
减肥
体重
药品审批
药物治疗
药效学
超重
作者
Anders Strathe,Eric Morris Bomberg,Garrit Jensch,Jonas Kildegaard,Nina Majlund Harder-Lauridsen,Daniel Weghuber,Rune Viig Overgaard
摘要
AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4-mg dose. MATERIALS AND METHODS: Simulation analyses combined pharmacokinetic, BMI and safety data from the adolescent STEP TEENS Phase 3 study (N = 201) and the adult semaglutide STEP studies (Phases 2-3; ~3100 participants). Data across doses (0.25-2.4 mg) were used to model concentration-time profiles, extrapolate percent change in BMI for 1.7 mg, estimate proportions achieving ≥ 5%, ≥ 10% and ≥ 15% BMI reductions and predict gastrointestinal adverse event (AE) incidence as a function of exposure. RESULTS: Modelled semaglutide concentrations over 68 weeks were similar between adolescents and adults; body weight was the main covariate influencing exposure. For adolescents, the 1.7-mg dose showed comparable efficacy to 2.4 mg (mean BMI change: -15.2% vs. -17.4%) and was significantly greater than placebo (p < 0.01). Predicted proportions achieving prespecified BMI reduction thresholds and gastrointestinal AE profiles were similar across populations and doses. CONCLUSIONS: PK/PD and safety modelling indicated 1.7 mg semaglutide provides comparable exposure, tolerability and meaningful BMI reduction in adolescents versus adults and versus 2.4 mg. These results supported approval of 1.7 mg for adolescents ≥ 12 years in the November 2024 Wegovy label, obviating a dedicated adolescent 1.7-mg placebo trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI